百奧賽圖－Ｂ：2023年度報告.pdf

1、Stock code 股份代號：2315百奧賽圖北京醫藥科技股份有限公司Biocytogen Pharmaceuticals(Beijing)Co.,Ltd.(A joint stock company incorporated in the Peoples Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司）Annual Report年度報告 20231 1百奧賽圖(北京)醫藥科技股份有限公司 二零二三年年報目錄 Contents主席報告2Chairmans Statement管理層討論與分析5Management Di

2、scussion and Analysis董事、監事及高級管理層52Directors,Supervisors and Senior Management企業管治報告66Corporate Governance Report董事會報告93Directors Report環境、社會及管治報告 142 Environmental,Social and Governance Report附錄一：環境關鍵績效指標摘要180 Appendix I:Environmental Key Performance Indicators Summary Table附錄二：聯交所 環境、社會及管治報告指引 索引18

3、2 Appendix II:Index of HKEXs Environmental,Social and Governance Reporting Guide獨立核數師報告 188 Independent Auditors Report綜合損益及其他全面收入表 195 Consolidated Statements of Profit or Loss andOther Comprehensive Income綜合財務狀況表 196 Consolidated Statements of Financial Position綜合權益變動表 198 Consolidated Statements

4、of Changes in Equity綜合現金流量表 199 Consolidated Cash Flow Statements綜合財務報表附註 202 Notes to the Consolidated Financial Statements財務概要 315 Financial Summary釋義 316 Definition公司資料 329 Corporate Information2Biocytogen Pharmaceuticals(Beijing)Co.,Ltd.Annual Report 2023主席報告 Chairmans StatementDear distinguishe

5、d shareholders,The year 2023 was indeed challenging.Amidst a complex and evolving macroeconomic environment and challenges arising from numerous policy shifts,the biopharmaceutical industry accelerated into an adjustment phase,displaying an overall trend of volatility and decline.Despite these turbu

6、lent internal and external conditions,our strategic investments in antibody development and overseas market expansion in recent years began to bear fruit.This drove continued rapid growth for the Company in 2023 and equipped us with the resources and capabilities to adapt swiftly to various internal